^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Shan Ke Yu (socazolimab)

i
Other names: STI-A1014, ZKAB 001, ZKAB001, STI A1014, STIA1014
Company:
Lee's Pharm, Sorrento
Drug class:
PD-L1 inhibitor
Related drugs:
28d
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. (PubMed, Oncologist)
Socazolimab combined with nab-paclitaxel has shown good safety and promising antitumor activity as first-line therapy in patients with advanced urothelial carcinoma.
P1 data • Journal • Combination therapy • Metastases
|
PD-1 (Programmed cell death 1)
|
albumin-bound paclitaxel • Shan Ke Yu (socazolimab)
5ms
New P3 trial • Metastases
|
Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Shan Ke Yu (socazolimab)
10ms
Trial completion
|
PD-L1 expression
|
carboplatin • etoposide IV • Shan Ke Yu (socazolimab)
almost2years
First-in-maintenance therapy for localized high-grade osteosarcoma: an open-label phase I/II trial of the anti-PD-L1 antibody ZKAB001. (PubMed, Clin Cancer Res)
Switching to maintenance using ZKAB001 showed an acceptable safety profile and provided preliminary evidence of clinical activity in localized osteosarcoma patients.
P1/2 data • Journal
|
MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
Shan Ke Yu (socazolimab)
over3years
Clinical • Enrollment change • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Shan Ke Yu (socazolimab)